Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VelCD (bortezomib + cyclophosphamide + dexamethasone) induction before high-dose chemotherapy in untreated multiple myeloma (DSMM XIa)
2005-003902-27Phase 2Completed
- Sponsor
- Janssen-Cilag
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Janssen-Cilag. Primary endpoint: Safety of VelCD induction therapy. Started Nov 2005; status: completed.
02
Drugs
bortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-003902-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003902-27.